

ICS 11.100.10

English Version

**Molecular in vitro diagnostic examinations - Specifications for  
pre-examination processes for FFPE tissue - Part 3: Isolated  
DNA**

Tests de diagnostic moléculaire in vitro - Spécifications  
relatives aux processus préanalytiques pour les tissus  
FFPE - Partie 3: ADN isolé

Molekularanalytische in-vitro-diagnostische Verfahren -  
Spezifikationen für präanalytische Prozesse für FFPE-  
Gewebeproben - Teil 3: Isolierte DNS

This Technical Specification (CEN/TS) was approved by CEN on 6 July 2015 for provisional application.

The period of validity of this CEN/TS is limited initially to three years. After two years the members of CEN will be requested to submit their comments, particularly on the question whether the CEN/TS can be converted into a European Standard.

CEN members are required to announce the existence of this CEN/TS in the same way as for an EN and to make the CEN/TS available promptly at national level in an appropriate form. It is permissible to keep conflicting national standards in force (in parallel to the CEN/TS) until the final decision about the possible conversion of the CEN/TS into an EN is reached.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, Former Yugoslav Republic of Macedonia, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and United Kingdom.



EUROPEAN COMMITTEE FOR STANDARDIZATION  
COMITÉ EUROPÉEN DE NORMALISATION  
EUROPÄISCHES KOMITEE FÜR NORMUNG

**CEN-CENELEC Management Centre: Avenue Marnix 17, B-1000 Brussels**

## Contents

Page

European foreword .....	3
Introduction .....	4
1 Scope .....	5
2 Normative references .....	5
3 Terms and definitions .....	5
4 General considerations .....	7
5 Outside the laboratory .....	7
5.1 Primary tissue collection manual .....	7
5.1.1 Information about the primary sample donor .....	7
5.1.2 Information on the primary tissue sample .....	8
5.1.3 Information on the primary tissue sample processing .....	8
5.2 Transport requirements .....	8
6 Inside the laboratory .....	9
6.1 Information on the primary tissue sample receipt .....	9
6.2 Formalin fixation of the specimen .....	9
6.3 Evaluation of the pathology of the specimen and selection of the sample .....	10
6.4 Post-fixation of frozen samples .....	11
6.5 Processing and paraffin embedding .....	11
6.6 Storage requirements .....	11
6.7 Isolation of DNA .....	12
6.7.1 General .....	12
6.7.2 General information for DNA isolation procedures .....	12
6.7.3 Using commercial kits .....	12
6.7.4 Using the laboratories' own protocols .....	13
6.8 Quantity and quality assessment of isolated RNA .....	13
6.9 Storage of isolated RNA .....	14
Annex A (informative) Impact of the storage temperature on DNA integrity in FFPE blocks of tissue .....	15
A.1 Introduction .....	15
A.2 Results .....	15
A.3 Conclusions .....	15
Bibliography .....	16

## European foreword

This document (CEN/TS 16827-3:2015) has been prepared by Technical Committee CEN/TC 140 “*In vitro* diagnostic medical devices”, the secretariat of which is held by DIN.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN [and/or CENELEC] shall not be held responsible for identifying any or all such patent rights.

According to the CEN-CENELEC Internal Regulations, the national standards organizations of the following countries are bound to announce this Technical Specification: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, Former Yugoslav Republic of Macedonia, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom.

## Introduction

Molecular *in vitro* diagnostics has enabled a significant progress in medicine. Further progress is expected by new technologies analysing signatures of nucleic acids, proteins, and metabolites in human tissues and body fluids. However, the profiles and/or integrity of these molecules can change drastically during primary sample collection, transport, storage and processing thus making the outcome from diagnostics or research unreliable or even impossible because the subsequent analytical assay will not determine the situation in the patient but an artificial molecular pattern generated during the pre-examination process. Studies have been undertaken to determine the influencing factors for DNA analysis from formalin fixed and paraffin embedded (FFPE) tissue. These studies demonstrated that a standardization of the entire process from primary sample collection to DNA analysis is needed. This Technical Specification draws upon such work to codify and standardize the steps for FFPE tissue with regard to DNA analysis in what is referred to as the preanalytical phase.

## 1 Scope

This Technical Specification gives recommendations for the handling, documentation and processing of FFPE tissue specimens intended for DNA analysis during the preanalytical phase before a molecular assay is performed. This Technical Specification is applicable to molecular *in vitro* diagnostic examinations (e.g., *in vitro* diagnostic laboratories, laboratory customers, developers and manufacturers of *in vitro* diagnostics, institutions and commercial organizations performing biomedical research, biobanks, and regulatory authorities).

DNA integrity in tissues can change before and during formalin fixation, processing and storage. Chemical modifications introduced into DNA during tissue fixation might lead to fragmentation and sequence alterations [1], changes in the methylation status or even structural changes which can lead to e.g., spurious copy number changes in array-CGH profiles [2]. These modifications of the DNA molecules can impact the validity and reliability of the analytical test results. Therefore, it is essential to take special measures to minimize the described modifications for subsequent DNA analysis.

## 2 Normative references

The following documents, in whole or in part, are normatively referenced in this document and are indispensable for its application. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

EN ISO 15189:2012, *Medical laboratories — Requirements for quality and competence (ISO 15189:2012, Corrected version 2014-08-15)*

ISO 15190, *Medical laboratories — Requirements for safety*

## 3 Terms and definitions

For the purposes of this document, the terms and definitions given in EN ISO 15189:2012 and the following apply.

### 3.1

#### **ambient temperature**

unregulated temperature of the surrounding air

### 3.2

#### **analytical phase**

processes that start with the isolated analyte and include all kinds of parameter testing or chemical manipulation for quantitative or qualitative analysis

### 3.3

#### **cold ischemia**

condition after removal of the tissue from the body until its stabilization or fixation

### 3.4

#### **DNA**

#### **deoxyribonucleic acid**

polymer of deoxyribonucleotides occurring in a double-stranded (dsDNA) or single-stranded (ssDNA) form

[SOURCE: EN ISO 22174:2005, 3.1.2]

### 3.5

#### **FFPE**

formalin fixation and paraffin embedding